AI-Driven Bioengineering Platforms Revolutionize Protein, Strain, and Drug Design with Multi-Billion Dollar Government Support

Precedence Research, a leading strategic research firm, presents a comprehensive analysis of the AI-driven bioengineering ...
Forbes

How Recursive AI Agents Can Help Turn Real-Time Data Into Smarter, Self-Improving Operations

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...
MarketWatch

Structure Therapeutics details positive trial data for a weight-loss pill, and the stock rockets

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...
Reuters

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
FierceBiotech

Wave, Structure stocks double on obesity data readouts

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...
Benzinga.com

Why Are Shares Of Recursion Pharmaceuticals Higher Today?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Morningstar

Structure details positive trial data for a weight-loss pill, and the stock rockets

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...
The Bakersfield Californian

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
GEN

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off. Plus: Stop Hiding Your Wins

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...
STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...